[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"erectile-dysfunction-ed\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:erectile-dysfunction-ed":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,78,107,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100640891","embolosclerotherapy-versus-deep-dorsal-vein-revascularization-in-venogenic-erectile-dysfunction-100640891",false,"NCT07604194","Embolosclerotherapy Versus Deep Dorsal Vein Revascularization in Venogenic Erectile Dysfunction","Embolosclerotherapy Versus Deep Dorsal Vein Revascularization for Erectile Dysfunction Due to Venous Leak: A Randomized Clinical Study","venogenic ED","Inclusion Criteria:\n\n* Cases with ED reporting difficulty in attaining or maintaining erection for at least 6 months.\n* All participants were sexually active, in a stable and heterosexual partnership, living with their sexual partner for at least the past one year, and have only one sexual partner.\n* The frequency of trying sexual intercourse was ≥1\u002Fweek.\n* Unsatisfactory response to PDE5i medication.\n* All cases suffered venogenic erectile dysfunction diagnosed by color flow Doppler sonography before and after intracavernous injection of vasoactive drugs or Dynamic infusion cavernosometry-cavernosography (selected cases), which indicated veno-occlusive dysfunction.\n\nExclusion Criteria:\n\n* Refusal to participate.\n* Major psychological or psychiatric disorders.\n* Non-vascular causes of ED including penile anatomic defects, any related neurological etiology or spinal cord injury, hypogonadism and hormonal disturbances.\n* History of previous venous surgery, suspected or proven deep venous thrombosis, history of Deep Vein Thrombosis.","MALE","40 Years","80 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Venous leakage is one of the causes of erectile dysfunction and can be managed using different treatment modalities, including surgical ligation and percutaneous embolization. This randomized clinical trial aims to evaluate and compare the efficacy, durability, safety, side effects, and complications of two treatment procedures-embolosclerotherapy of the periprostatic plexus and deep dorsal vein revascularization-in the management of erectile dysfunction caused by venous leak.",[28,29],"Erectile Dysfunction Due to Venous Disorder","Erectile Dysfunction (ED)",[31,32,33,34,35,36,37],"Venogenic erectile dysfunction","Onyx","Endovascular embolization","Venous leak","deep dorsal vein","revascularization","polidocanol","NOT_YET_RECRUITING","2026-05-22",{"date":41,"type":42},"2026-05-27","ACTUAL",{"date":44,"type":22},"2026-06-20",{"date":46,"type":22},"2027-09-20",{"name":48,"class":49},"Mansoura University Hospital","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100611904","phase-4-ipp-placement--intracavernosal-block-100611904","NCT07246642","IPP Placement & Intracavernosal Block","Randomized Controlled Trial of Intracorporal Local Anesthesia vs Saline Prior to Placement of Inflatable Penile Prosthesis Placement","IPP","Inclusion Criteria:\n\n* Any patient undergoing primary three-piece inflatable penile prosthesis (IPP) placement at Lexington Medical Center\n\nExclusion Criteria:\n\n* Patients undergoing revision and\u002For secondary IPP placement\n* Patients taking prescribed narcotic medications at the time of IPP surgery\n* Patients undergoing concomitant Peyronie's Disease surgery (modeling, plication, grafting) at the time of IPP surgery\n* Patients with liver and\u002For renal disease","21 Years",{"count":60,"type":22},100,[62],"PHASE4","The inflatable penile prosthesis (IPP) is the gold standard for surgical management of erectile dysfunction (ED) and there is no consensus on the best postoperative pain management regimen. In the wake of the opioid epidemic, postoperative pain management is heavily scrutinized. The National Institute of Health estimated over 81,000 individuals died following overdose of any opioids in 2022 alone; of these, over 14,000 deaths were linked to prescription opioids. Thus, strategies to minimize postoperative pain should not only improve patient experience but also lessen the need to escalate to opioid usage.",[29],[66,67,68],"inflatable penile prosthesis (IPP)","Pain management","Penile pain",{"date":70,"type":42},"2026-05-26",{"date":72,"type":22},"2026-09",{"date":74,"type":22},"2027-10",{"name":76,"class":49},"Wake Forest University Health Sciences",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":77},"100638916","phase-2-a-single-arm-dose-escalation-of-an-intraurethral-alprostadil-paste-for-erectile-dysfunction-100638916","NCT07601646","A Single-Arm, Dose Escalation of an Intraurethral Alprostadil Paste for Erectile Dysfunction","Phase 2 Clinical Trial of ST-04 Intraurethral Paste for Erectile Dysfunction","Inclusion Criteria:\n\n* Have had a confirmed clinical diagnosis of ED for more than three months based upon IIEF\n* Have failed PDE5 inhibitor therapy (inability to achieve an erection with adequate rigidity to allow penetrative sex)\n* Ability to take oral medication (sildenafil) and be willing to adhere to the study intervention regimen\n* Engaged in heterosexual relationship with partner for a minimum of 6 months\n\nExclusion Criteria:\n\n* History of unstable medical or psychiatric condition that, in the opinion of the principal investigator, could impact the patient's ability to complete the study investigations or protocol.\n* Spinal cord injury, or penile anatomical abnormalities\n* Cardiovascular conditions that prevent sexual activity (NYHA Class II or higher, any angina, or uncontrolled CHF or severe coronary artery disease)\n* History of myocardial infarction, stroke, or life-threatening arrhythmia within 6 months prior to enrollment into the study\n* Use of anti-androgens, or oral or injectable androgens\n* Documented hypotension or known orthostatic hypotension\n* Use of oral, topical or sublingual nitrates within 3 months prior to enrollment into the study\n* Hepatic (Child-Pugh Class C) or renal failure (eGFR \\\u003C 30)\n* Inadequate response to intracavernosal injection therapy previously\n* Peyronie's disease or Meatal stenosis","75 Years",{"count":87,"type":22},83,[89],"PHASE2","This is a single arm dose escalation trial of a mucoadhesive intraurethral polymer suspension of alprostadil (ST-04) and will investigate the efficacy of 3 dose levels of ST-04 in adult males with a clinical diagnosis of Erectile Dysfunction (ED). This study aims to determine if ST-04, with or without sildenafil, will improve erectile function (EF) compared to baseline.\n\nParticipants in this study will receive ST-04, a new formulation containing the vasodilator, alprostadil which is known to be an effective drug in treating erectile dysfunction. ST-04 will be dispersed along the urethra, forming a hydrogel which adheres to the lining of the urethra with the goal of penile tumescence and erection. Participants may receive up to 3 dose level escalations of ST-04 over a 12-week period, for a total of up to 11 administrations of ST-04. Dose escalation may also be done with and without sildenafil.",[29,92,93],"Erectile Dysfunctions","Erectile Function",[95,93,96,97],"Erectile Dysfunction","Alprostadil","Sildenafil","RECRUITING","2026-05-20",{"date":39,"type":42},{"date":102,"type":22},"2026-05",{"date":104,"type":22},"2027-05",{"name":106,"class":49},"Ryan Flannigan, MD",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":138},"100613990","evaluation-of-the-rigicon-infla10-inflatable-penile-prosthesis-ipp-for-erectile-dysfunction-100613990","NCT07273773","Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) for Erectile Dysfunction","Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) A Prospective, Multicenter, Single-Arm Performance-Goal Study","UNITED","Inclusion Criteria:\n\n1. Male ≥22 years of age.\n2. Diagnosed with erectile dysfunction (impotence).\n3. Agree to receive Infla10® three-piece IPP as an ED treatment.\n4. Willing to complete all protocol required for follow-up visits and tests.\n\nExclusion Criteria:\n\n1. Contraindication to general anesthesia.\n2. Known allergy or sensitivity to product materials as indicated in the device labeling.\n3. Previous penile prosthesis or prior enlargement surgeries\n4. Diagnosed penile sensory neuropathy.\n5. Patients who are receiving immunosuppressive drugs or have a history of kidney transplantation.\n6. Patients who are receiving chemotherapy at the time of enrolment.\n7. Diagnosed with fibrotic disease, such as priapism or Peyronie's disease or Chordee.\n8. Compromised immune system, such as systemic lupus erythematosus, discoid lupus, or scleroderma.\n9. Uncontrolled diabetes (HbA1c ≥ 9.0% \\[≈75 mmol\u002Fmol\\], measured within 90 days prior to surgery.\n10. Bleeding disorder or coagulopathy that may in the judgment of the investigator preclude safe procedure.\n11. Active urogenital infection or active skin infection in region of surgery or systemic infection at the time of assessment.\n12. Clinically significant comorbidities or presence of unstable conditions (e.g. cardiovascular, lung, renal \\[serum creatinine \\> 2.0 mg\u002Fdl\\], hepatic, bleeding disorders, or metabolic impairment) that may confound the results of the study or in the judgment of the physician investigator preclude safe procedure.\n13. Lacking manual dexterity or mental abilities necessary to operate the device.\n14. Expected life expectancy \\\u003C two years.\n15. Unwilling or unable to sign the Informed Consent.\n16. Unwilling or unable to comply with the follow-up study requirements.\n17. Psychogenic erectile dysfunction\n18. Currently participating in an investigational drug or another investigational device exemption (IDE) study.\n19. The cognitively challenged subjects and subjects with any cognitive disorder that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affects the ability to complete the study questionnaires.\n20. Incarcerated subjects\n21. Subjects who are currently using, or who have not previously attempted and failed, standard non-surgical ED therapies including oral or topical treatments.","22 Years",{"count":117,"type":22},182,[25],"This study evaluates the long-term safety and effectiveness of the Rigicon Infla10® Inflatable Penile Prosthesis in patients with erectile dysfunction. The study follows patients implanted with the Rigicon Infla10® Pulse™ Dynamic Inflatable Penile Prosthesis for up to 3 years after implantation.",[29],[122,123,124,125,126,127],"Rigicon","Infla10","inflatable penile prosthesis","penile prosthesis","Dynamic","erectile dysfunction","2026-02-25",{"date":130,"type":42},"2026-02-27",{"date":132,"type":42},"2026-01-26",{"date":134,"type":22},"2029-07",{"name":136,"class":137},"Rigicon, Inc.","INDUSTRY",7,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":147,"sex":17,"minAge":148,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":4},"100618464","the-feasibility-of-using-dornier-machine-in-patients-with-erectile-dysfunction-a-pilot-study-100618464","NCT07331961","The Feasibility of Using Dornier Machine in Patients With Erectile Dysfunction, a Pilot Study.","Assessment of the Feasibility and Clinical Efficacy of Low-Intensity Extracorporeal Shockwave Therapy (Li-ESWT) Using the Dornier System in Patients With Vasculogenic Erectile Dysfunction: A Pilot Study","DED-Pilot","Inclusion Criteria:\n\n* Patients with erectile dysfunction (ED) confirmed by clinical assessment and penile duplex Doppler ultrasound\n\nExclusion Criteria:\n\n* 1-Coagulapathy. 2-Penile prosthesis. 3-Post Radical Cystectomy 4-Intellectual disability 5-Skeletal abnormalty",true,"30 Years",{"count":150,"type":22},30,[25],"Extracorporeal Shockwave Therapy (ESWT) is a well-established modality for treating various urological and musculoskeletal conditions. Recently, its application has expanded to include vasculogenic erectile dysfunction (ED), primarily due to its ability to trigger neo-angiogenesis and significantly improve penile blood flow.",[29],[127,155,156],"low intensity shock wave treatment","extracorporeal shock wave therapy","2026-01-08",{"date":159,"type":42},"2026-01-12",{"date":161,"type":22},"2026-01-01",{"date":163,"type":22},"2026-03-30",{"name":165,"class":49},"Assiut University"]